Piyasa kapalı· · NOK · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Hofseth BioCare ASA ("HBC" or the "Company") today announces the appointment of Leif Arne Giske as new Chief Financial Officer (CFO) of the HBC Group, effective immediately. Mr. Giske has been with Hofseth BioCare since 2013 and previously held the position of Group Accounting Manager. Through this role he has had overall responsibility for the Group's accounting, financial reporting and control functions. Mr. Giske holds 3,339,384 shares in HBC and will be part of the Company's executive manage
HBC recorded total operating revenues of NOK 65.7 million in the second quarter of 2026, compared to NOK 68.4 million in the same period last year. Net operating revenues were NOK 63.1 million, down from NOK 67.8 million in Q2 2025. EBITDA for the quarter was negative NOK 2.7 million, compared to negative NOK 5.4 million in Q2 2025. The Operational EBITDA* amounted to negative NOK 0.6 million (positive NOK 1.3 million in Q2 2025), excluding non-recurring and strategic development costs such as c
Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 3 July 2026 regarding the private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million. The Private Placement was divided into two tranches and the second tranche of 32,819,999 Offer Shares ("Tranche 2") was approved at the extraordinary
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.